Logo

EDIT

Editas Medicine, Inc.

EDIT

Editas Medicine, Inc. • NASDAQ
$2.41 ▲ 0.42% (+0.01)
Market Cap $205.11 M
52w High $4.54
52w Low $0.91
Dividend Yield 0%
P/E -1.03
Volume 1.01M
Outstanding Shares 85.11M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $7.543M ▲ $32.091M ▼ $-25.117M ▲ -332.984% ▲ $-0.28 ▲ $-21.997M ▲
Q2-2025 $3.578M ▼ $55.122M ▼ $-53.235M ▲ -1.488K% ▲ $-0.63 ▲ $-49.381M ▲
Q1-2025 $4.658M ▼ $80.821M ▲ $-76.088M ▼ -1.633K% ▼ $-0.92 ▼ $-71.955M ▼
Q4-2024 $30.604M ▲ $77.197M ▲ $-45.395M ▲ -148.33% ▲ $-0.55 ▲ $-32.98M ▲
Q3-2024 $61K $64.128M $-62.141M -101.87K% $-0.75 $-60.542M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $165.648M ▼ $201.751M ▼ $188.298M ▼ $13.453M ▼
Q2-2025 $178.501M ▼ $210.581M ▼ $191.392M ▼ $19.189M ▼
Q1-2025 $220.964M ▼ $263.652M ▼ $201.232M ▼ $62.42M ▼
Q4-2024 $269.913M ▲ $341.589M ▲ $207.315M ▲ $134.274M ▼
Q3-2024 $265.088M $327.567M $151.933M $175.634M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-25.117M ▲ $-30.843M ▲ $39.573M ▼ $17.169M ▲ $25.899M ▲ $-31.276M ▲
Q2-2025 $-53.235M ▲ $-50.212M ▼ $42.65M ▼ $7.412M ▲ $-150K ▼ $-50.212M ▼
Q1-2025 $-76.088M ▼ $-47.799M ▲ $56.387M ▲ $-1.437M ▼ $7.151M ▼ $-47.913M ▲
Q4-2024 $-45.395M ▲ $-50.762M ▲ $30.958M ▼ $55.513M ▲ $35.709M ▲ $-51.302M ▲
Q3-2024 $-62.141M $-52.588M $83.979M $0 $31.391M $-55.509M

Revenue by Products

Product Q1-2025Q2-2025Q3-2025
Reportable Segment
Reportable Segment
 $0 ▲$0 ▲$10.00M ▲

Five-Year Company Overview

Income Statement

Income Statement Editas is still very much a research-stage company from a financial standpoint. Revenue has been minimal and somewhat lumpy over the past few years, likely tied to collaborations or milestone payments rather than product sales. The company consistently spends far more on research, development, and overhead than it brings in, leading to ongoing operating losses and negative net income every year. Losses widened during some years and then improved somewhat recently, but the business is clearly not yet financially self-sustaining and remains dependent on external funding to support its R&D efforts.

Balance Sheet

Balance Sheet The balance sheet shows a company that once held a stronger cushion of assets and equity but has gradually been drawing that down. Total assets have trended lower from earlier peaks, and shareholders’ equity has shrunk meaningfully as cumulative losses have piled up. Cash remains a key component of assets and is still present at a meaningful level, but it has not been growing and does not appear to be replenished by operations. On the positive side, debt levels are low and stable, so the capital structure is not heavily burdened by borrowings. The main concern is the gradual erosion of the equity base as the company finances its science through losses.

Cash Flow

Cash Flow Cash flow patterns reinforce the picture of a company in heavy investment mode. Operating cash flow has been consistently negative, reflecting that day-to-day operations consume cash rather than generate it. Free cash flow is also predictably negative each year, only slightly more so than operating cash flow, which suggests capital spending is relatively modest compared with research and operating costs. This pattern is typical for early-stage biotech: the business is burning cash to advance its pipeline, and will likely need to rely on equity raises, partnerships, or other external funding over time unless it secures substantial new revenue sources.

Competitive Edge

Competitive Edge Editas occupies a specialized niche in the CRISPR landscape, with a notable focus on editing genes directly inside the body rather than primarily outside it. Its competitive strength comes from a broad and deep patent position licensed from the Broad Institute, covering important CRISPR tools (including both Cas9 and Cas12a). That intellectual property and the dual-nuclease approach give it flexibility and potential leverage in negotiations and partnerships. The company is, however, competing against other well-funded gene-editing players that are further along clinically in some indications. This means Editas has a strong scientific and legal foundation but must still prove in patients that its approach can match or exceed the clinical successes seen by rivals.

Innovation and R&D

Innovation and R&D Innovation is the core of Editas’s story. The company is pushing a differentiated CRISPR platform built around both Cas9 and an engineered Cas12a enzyme, with an emphasis on improving precision and limiting unwanted edits. A standout feature is its gene upregulation strategy, which aims to boost the body’s own protective genes instead of only fixing defective ones. It is also investing heavily in targeted lipid nanoparticles to deliver editing tools directly to specific tissues in the body. The pipeline, including candidates like EDIT-401 for cardiovascular disease, is still early and largely preclinical, so scientific promise has not yet translated into human proof-of-concept. R&D spending remains substantial relative to the company’s small revenue base, underscoring both the ambition and the risk: success could be transformative, but clinical and regulatory hurdles are significant and timelines are long.

Summary

Financially, Editas looks like a classic early-stage biotechnology company: very low and irregular revenue, persistent losses, steady cash burn, and a gradually shrinking equity cushion, though with limited debt. Strategically, it stands out through a strong patent position, a focus on in vivo gene editing, and a sophisticated technology stack that includes dual nucleases, gene upregulation, and proprietary delivery systems. The key unknown is execution: moving from promising lab science to convincing human data. Until there is clear clinical proof-of-concept and a path to meaningful revenue, the company’s story will remain one of high scientific potential paired with substantial financial and development risk.

NEWS

November 10, 2025 · 7:00 AM UTC

Editas Medicine Announces Third Quarter 2025 Results and Business Updates

Read more

November 3, 2025 · 9:00 AM UTC

Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025

Read more

October 9, 2025 · 11:01 AM UTC

Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress

Read more

October 6, 2025 · 9:00 AM UTC

Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences

Read more

September 2, 2025 · 7:00 AM UTC

Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate

Read more